Brian E. Ward

Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA.

The DNA Repair Co. develops cancer diagnostics solutions. The firm produces DNA Repair biomarkers which reveal therapeutic solutions for cancer drugs. The company was founded by Alan D’Andrea, William A. Haseltine, Michael B. Yaffe, and Markus Grompe and is headquartered in Boston, MA.

Genzyme Genetics, Inc. provides laboratory testing and diagnostic services specifically for reproductive and oncology tests. It provides tests for cystic fibrosis carriers and cancers. The company is headquartered in Westborough, MA.

Myriad Genetic Laboratories, Inc. provides cancer predisposition testing services. It operates as a biopharmaceutical company that focuses on developing therapeutic and predictive medicine products. The company was founded on October 11, 1995 and is headquartered in Salt Lake City, UT.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.